



## ARO A BIOSURGERY QUARTERLY RESULTS WEBINAR

---

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'ARO A' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on **Tuesday 30 January 2024, at 9 AM AEDT**, to discuss the December Quarterly Results.

Investors and interested parties can register to attend the webinar via the following link:

[https://us02web.zoom.us/webinar/register/WN\\_6C1SiK4HQy6fPgEFv9KamA](https://us02web.zoom.us/webinar/register/WN_6C1SiK4HQy6fPgEFv9KamA)

Questions can be submitted before the webinar to [investor@aroabio.com](mailto:investor@aroabio.com) or during the webinar using the Q&A function on Zoom.

---

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

### **About Aroa Biosurgery:**

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary ARO A ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 6 million ARO A products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, ARO A is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). [www.aroabio.com](http://www.aroabio.com)

### **Contacts**

[investor@aroabio.com](mailto:investor@aroabio.com)

+ 64 21 744 915